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Abstract 
Purpose: To screen an hTfR affinity peptide and investigate its activity in vitro. 
Methods: hTfR affinity phage clones were screened from 7-mer phage display library, and their binding 
ability evaluated by enzyme-linked immunosorbent assay (ELISA). A competitive assay was performed 
to discover the peptide BP9 (BP9) binding site on the cells. The inhibitory effect of BP9 on the cells was 
determined using thiazolyl blue (MTT) assay. EGFP-BP9 fusion protein was expressed in E. coli, and its 
binding and localization on cells were determined by fluorescence microscopy and confocal microscopy, 
respectively.  
Results: After three rounds of panning, recovery efficiency was 48-fold higher than that of the first 
round. The peptide BP9 sharing 2 identical amino acids to Tf showed high-affinity to hTfR, and 
possessed strong proliferation inhibition ratio on different tumour cells of 70 % (HepG2 cells)/77 % 
(SMMC-7221 cells) at a concentration of 0.1 mM, and 85 % (HepG2 cells)/81 % (SMMC-7221 cells) at a 
concentration of 0.001 mM for 48 h. The recombinant protein EGFP–BP9 could bind to tumour cells and 
gain entry via the endocytic pathway. 
Conclusion: BP9 can bind to TfR and inhibit the proliferation of the tumour cells over-expressing TfR. 
The DNA sequence coding for BP9 was able to target the macromolecule to combine with TfR. BP9 
may possess potential applications in cancer therapy. 
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Phage display is a selection technique in which a 
library of peptide or protein variants is expressed 
on the outside of a phage virion, while the 
genetic material encoding each variant resides 
on the inside [1]. Phage display technology 
shows good prospects in targeted therapies, and 
peptides are promising molecules to selectively 
deliver imaging or therapeutic agents to tumours. 
A number of peptides have been identified by 
phage display for targeting different tumors and 
cell types [2-4]. Among these, tumor homing 
peptides RGD [2,5] and NGR [6] sequences 
have received particular attention. The 
experimental results show that these peptides 
can significantly increase the enrichment of the 
drug in the target tissue, improve efficacy, and 
reduce the side effects of drugs [7-9]. 
 
The transferrin receptor (TfR) has been reported 
to be ubiquitously expressed and is over-
expressing 100-fold in many tumour cells and 
brain capillary endothelial cells [10]. Because of 
its expression pattern and pathway 
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characteristics, the hTfR is an attractive target for 
therapeutics for tumour and central nervous 
system diseases.  
 
At present, scientists have succeeded in 
connecting many therapeutic molecules to hTfR’s 
natural ligand transferrin (Tf) and to hTfR 
antibody (OX26), and they have achieved good 
results in oncology and central nervous system 
diseases [11,12]. However, the high 
concentration of endogenous Tf and the 
relatively high molar weight of Tf in blood make 
TfR difficult for the construction of drug delivery 
systems [13]. In order to identify peptides that 
can prevent TfR from binding to its ligand Tf, we 
have attempted in this study to isolate a high-
affinity from a 7-mer phage display library, and 
the functions of peptide BP9 were further studied 





Cell lines and regents  
 
BP9 peptide and FITC-BP9 peptide were 
synthesized by Guangzhou Teli biotechnology 
co., Ltd. HepG2, SMMC-7721 and L-O2 cell lines 
were purchased from the Type Culture Collection 
of the Chinese Academy of Sciences (Shanghai, 
China). They were all maintained at 37 °C in a 
humidified atmosphere of 5 % CO2 and cultured 
in RPMI-1640 supplemented with 10 % (v/v) 
FBS. The hTfR (R&D, USA) was used as a target 
molecule. The Ph.D.-7TM Phage Display Peptide 
Library kit (New England Biolabs, Beverly, MA, 
USA) was used to screen specific peptides 
binding to hTfR. E. coli ER2738 (New England 
Biolabs) was used for M13 phage propagation. 
 
In vitro panning 
 
Bio-panning was performed as described below. 
A solution of 64 μg/ml of the hTfR in 0.1 M 
NaHCO3 (pH 8.6) was prepared, 150 μl of this 
solution was added to each well in a 96-well 
plate and the plates incubated overnight at 4 °C. 
The coating solution was poured off and blocking 
buffer bovine serum albumin (BSA) at 5 mg/ml in 
0.1 M NaHCO3 was added and incubated for 1 h 
at 4 °C. The BSA was discarded and each well 
washed with 0.1 % (v/v) Tween-20 in 0.1 % 
TBST and 10 μl of original library (2 × 1011 
plaque-forming units, PFUS) were diluted in 100 
μl TBST and added to the plate well for 2 h at 
room temperature with gentle agitation. After 
washing with 0.1 % TBST, the bound phages 
were eluted with 0.2 M glycine-HCl (pH 2.2) and 
neutralized with 1 M Tris-HCl (pH 9.1). Elute 
phages were amplified in 20 ml Luria Bertani 
medium containing E. coli ER2738, purified by 
precipitation with polyethylene glycol PEG/NaCl, 
which was titrated as described in the standard 
protocol (NEB), and used for additional rounds of 
biopanning. The conditions of two additional 
rounds of selection were performed under more 
stringent conditions. The concentration and 
incubation time of hTfR was gradually reduced 
(32 mg/ml for 1.5 h and 16 mg/ml for 1 h in the 
2nd and 3rd rounds, respectively), while the 
concentration of Tween-20 was gradually 
increased (0.3 % and 0.5 % for the 2nd and 3rd 
round, respectively). 
 
Enzyme-linked immunosorbent assay (ELISA) 
for analysing binding ability  
 
Approximately 1×1011 pfu of phages were added 
to each well for 1 h at room temperature and the 
unbound phages were washed using the 
procedure described above for in vitro panning. 
After washing with 0.1 % TBST, 200 μl of 
horseradish peroxidase (HRP)-anti-M13 (1:5000) 
was added to each well and incubated at room 
temperature for 1 h with agitation. The bound 
antibody was visualized using 3, 3′, 5, 5′-
tetramethyl- benzidine (TMB) and terminated by 
50 μl/well of 2 M H2SO4 after 20 min. The 
absorbance was measured at 450 nm. 
 
Sequence analysis of selected phages and 
peptide synthesis 
 
The phage ELISA binding assay showed six 
phages with higher OD value than the others, 
and their sequences were analysed (Shanghai 
Invitrogen Corporation, China). Homologous 
analysis was conducted using BioEdit programs. 
The peptide with the same DNA sequence of the 
NO.9 phage was synthesised.  
 
Competitive inhibition assay 
 
Cells were inoculated on 24-well tissue culture 
plates overnight. They were then washed and 
incubated in serum-free medium for 3 h and pre-
incubated with 1 % (w/v) BSA to block 
nonspecific binding at room temperature for 1 h. 
The synthetic peptide (0.00001 mM, 0.0001 mM, 
0.001 mM, 0.01 mM, 0.1 mM) was diluted in PBS 
and incubated with the cells at 37 °C for 3 h, then 
incubated with 1×1011 pfu/well of phage clones at 
37 °C for 2 h. The bound phages were recovered 
and titered.  
 
Cell viability assay 
 
Cells were seeded in a density of 6×103 cells of 
200 μl per well in 96-well plates and cultivated for 
24 h. After being starved in serum-free RPMI 
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1640 with 0.4 % (v/v) FBS for 24 h, the cells 
were treated with serially diluted peptide BP9 
(0.00001 mM, 0.0001 mM, 0.001 mM, 0.01 mM, 
0.1 mM) for 48 h and peptide BP9 (0.001 mM) for 
different time (6 h, 12 h, 18 h, 24 h, 30 h, 36 h, 
42 h and 48 h). The viability of cells was 
determined by the MTT assay. MTT (20 μl) was 
added to each well and incubated with the cells 
for 4 h. To it was added 150 μl/well of dimethyl 
sulfoxide (DMSO) to dissolve the crystals. Finallt, 
the absorbance was measured at 490 nm to 
determine the number of viable cells.  
 
EGFP–BP9 and EGFP production and 
purification  
 
The pEGFP-N1 was used as the template. The 
forward primer was designed as 5’-
GGAATTCCATATGCATCACCACCACCACCAC
GTGAGCAAGGGCGAGGAGCT-3’ with NdeⅠ 
and histidine-tagged(underline), and the reverse 
primer was 5’-CCGGAATTCTTAAGAACGATTA 
TGCAGATGAGCCTTGTACAGCTCGTCCATGC
C-3’ with short peptide coding region, terminator 
and EcoR I (underline). The EGFP-BP9 gene 
was amplified by PCR. The PCR reactions were 
carried out for 30 cycles: 94 °C, 1 min; 58 °C, 45 
sec; and 72 °C, 1 min. After being digested by 
Nde I and EcoR I, the EGFP-BP9 fragment was 
subcloned into Nde I-EcoR I sites of pET-22b, 
generating the recombinant plasmid pET-
22b/EGFP-BP9. Then, the plasmids were 
transformed into BL21/DE3 E. coli and 
expression was induced for 4 h with 1 mM 
isopropylthio-β-D-galactoside (IPTG) when the 
cell culture reached a density of OD600 = 0.6. The 
induced cells were harvested and lysed by 
sonication in binding buffer (1×PBS). Cell lysates 
were passed over a HisTrap nickel column. The 
column was washed with wash buffer (1×PBS, 
30 mM imidazole, pH 7.2) and eluted using an 
imidazole gradient (1×PBS, 90, 120, 150 mM 
imidazole, pH 7.2). Purified EGFP and BP9 
fusion EGFP were equally fluorescent, indicating 
that the EGFP-BP9 fusion proteins had the 
correct conformation and were active in E. coli. 
The purified protein was further assayed by 
SDS/PAGE, followed by Coomassie staining and 
Western blot analysis with an EGFP monoclonal 
antibody (1:500). Protein concentrations were 
determined with a Pierce BCA Protein Assay Kit 
(Thermo scientific, 3747 N. Meridian Rd., 
Rockford, IL 61101 USA) with bovine serum 
albumin as a standard. The purified EGFP fusion 
protein was aliquoted in PBS and stored at -80 
°C. 
 
Binding of the recombinant protein EGFP–
BP9 
 
HepG2 and SMMC-7221 cells (1 × 105) were 
inoculated in 24-well tissue culture plates. The 
dishes were washed and incubated in serum-free 
RPMI-1640 at 37 °C for 1 h. His-EGFP-BP9 
fusion proteins (8 μM) were added to the culture 
medium and incubated at 37 °C for the indicated 
time. The cells were washed with PBS to remove 
non-specific extracellular proteins bound to the 
cell surface. The cells were suspended in PBS 
and observed by fluorescence microscope (IX 
81,Olympus Corporation, Japan). 
 
Localisation of the recombinant protein 
EGFP–BP9 
 
HepG2, SMMC-7221 and L-O2 cells were grown 
on 15 mm glass-bottom dishes to 50 – 75 % 
confluence. The dishes were washed and 
incubated in serum-free RPMI-1640 at 37 °C for 
1 h. Histidine-tagged EGFP-BP9 (8 μM) was 
applied to the cells in serum-free RPMI-1640 at 
37 °C for 1 h. The cells were washed with PBS, 
then fixed in 4 % (v/v) formaldehyde for 20 min at 
room temperature, and stained for 30 min with 4', 
6-diamidino-2-phenylindole (DAPI) to visualise 
the nuclei. The dishes were mounted in antifade 
medium. Then cells were then viewed under 





All data were presented as mean ± SEM. All 
statistical analyses were performed using 
GraphPad Prism software, version 5.01. 
Comparison of parameters among two groups 
was made by Student’s test, while one-way 
ANOVA followed by Tukey’s multiple comparison 
test was used for multiple comparison data. The 
differences were considered to be significant at p 




Selection of specific hTfR-binding phage 
clones 
In this study, Ph.D.-7TM Phage Display Peptide 
Library was used to isolate phages that could 
specifically bind to hTfR. As shown in Table 1, 
both phage titre and recovery efficiency were 
significantly increasing after each round of 
panning. After three rounds of panning, recovery 
efficiency was 48-fold higher (from 2.56×10-5 to 
3.3×10-7) than that of the first round, suggesting 
that the phage clones specifically bound to hTfR 
were successfully enriched. In order to identifi 
the binding ability of selected phage clones,  
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Table 1: Enrichment of phages for each round of selection from the phage display library 
 




(pfu/ml) Recovery (%) 
1 64 1.0×1011 1.3×105 1.3×10-6 
2 32 4.4×1011 1.95×106 4.43×10-6 
3 16 1.5×1011 9.4×106 6.26×10-5 
﹡pfu, Plaque forming unit 
 
Figure 1: Appraisal of twenty phage clones’ binding ability by ELISA. The blocking buffer without hTfR was used 
as negative control. Data presented are the mean O.D. values (±S.D.) of triplicate samples; ﹡p < 0.05, ﹡﹡p < 
0.01, ﹡﹡﹡p < 0.001versus blocking buffer sample 
 
Table 2: Amino acid sequences of specific hTfR-binding peptides and compare with Tf 
 
Phage no.. Peptide no.. Seuqence
a 
(N-C) Similarities to Tf Theoretical PI GRAVY 
P3 BP3 HAIYPRH 0.0014327 8.76 -1.071 
P6 BP6 FLHSAGS 0.0042980 6.74 0.457 
P9 BP9 AHLHNRS 0.0042980 9.81 -1.371 
P11 BP11 VPRSMEM 0.0042980 5.97 -0.343 
P15 BP15 HENQTRQ 0.0014327 6.75 -3.200 
P20 BP20 MPVPRLL 0.0042980 9.50 0.857 
 Tf651-657b FRSETKD  6.07 -2.014 
 Tf   6.81 -0.377 
a Bold letters show the conserved motifs; b One segments of Tf that shows partial homology with the 
peptides of the selected phage clones. 
 
twenty independent phage clones which were 
randomly picked after the third panning were 
tested by ELISA. As shown in Fig 1, six clones 
had showed high bindng ability to hTfR (clones 3, 
6, 9, 11, 15, 20) when compared to negative 
control, suggesting that they may have higher 
affinity for hTfR than the other clones. Then we 
selected the six clones for sequencing. 
 
DNA sequence analysis and property 
prediction of selected phage clones 
 
The hTfR binds to ligand transferrin (Tf) and 
provides iron to maintain cellular survival. 
Therefore, the amino acid sequences of selected 
peptides were compared with the Tf. As shown in 
Table 2, most sequences consisted of basic 
amino acids. The phage clone P9 (peptide was 
named BP9) as well as P11 showed the highest 
sequence similarity to Tf (0.004298, PAM250 
Matrix). They contain 2 identical amino acids 
(RS) to the peptide of the site 651-657 
(FRSETKD) of Tf (Genebank ID AAB22049). In 
the physiological condition, BP9, BP11 and Tf651-
657 all carry the negative charges and they are all 
the hydrophilic peptides. Moreover, the 
hydrophobic profile of BP9 was similar to the 
peptide Tf651-657. Taken together, these data 
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suggest that the peptide BP9 sharing 2 identical 
amino acids to the ligand Tf may bind hTfR via 
electrostatic interactions and may interrupt hTfR 
binding to its ligand Tf. Consequently, the 
peptide BP9 was chosen for further study. 
 
 Competitive inhibition assay and inhibition 
of cell proliferation 
 
A peptide competitive inhibition assay was 
performed to discover whether the synthetic 
peptide BP9 and the selected P9 phage clone 
(which displaying peptide BP9 sequence) 
competed for the same binding site. The BP9 
peptide was used as the inhibitor of P9 phage 
clone. In this work, we chose the HepG2 and 
SMMC-7221 cells because both them are liver 
cancer cells and over-expressing TfR [14,15]. As 
shown in Fig 2A, with an increase in the 
concentration of BP9, the titre of the phages 
recovered from the HepG2 and SMMC-7221 
cells decreased and the inhibition rate gradually 
increased. At 0.1 mM, the inhibition ratio for the 
binding of P9 phages to HepG2 and SMMC-7221 
cells was approximate 67 % and 57 %, 
respectively, which demonstrated BP9 strongly 
inhibited the binding of P9 phages to HepG2 and 
SMMC-7221 cells. However, BP9 had no effect 
on the binding of the M13KE phages to HepG2 
and SMMC-7221 cells. In addition, BP9 also had 
no effect on the binding of the P9 phages to L-O2 
cells, which were normal liver cells and lack of 
TfR. The P9 phages binding to HepG2 and 
SMMC-7221 cells was mediated by BP9, 
indicating that they competed for the same site of 
TfR. 
 
To determine whether BP9 could inhibit the 
proliferation of tumour cells, we had used an 
MTT assay to investigate the effects of BP9 on 
the proliferation of HepG2, SMMC-7221 and L-
O2 cells. The starved cells were treated with 
various concentrations of BP9 for 48 h (Fig 2B) 
and 0.001 mM (Fig 2C) of BP9 for different time. 
BP9 had a dose-dependent and time-dependent 
inhibitory effect on the proliferation of HepG2 and 
SMMC-7221 cells. When the concentration of 
BP9 was 0.1mM, the inhibition ratio was 
approximate 70 % and 77 % for HepG2 and 
SMMC-7221 cells, respectively, and when the 
cells were treated with 0.001 mM of BP9 for 48 h, 
the inhibition ratio was approximate 85 % and 81 
% for HepG2 and SMMC-7221 cells, 
respectively. However, BP9 had no effect on the 
L-O2 cells, implied that BP9 could target 
specifically with TfR and may interrupt TfR 
binding to its ligand Tf. 
 
EGFP–BP9 and EGFP production, purification 
and binding on tumour cells 
 
In order to further research whether the BP9 
peptide could mediate other macromolecules to 
combine with TfR, the DNA sequence coding for 
peptide BP9 were fused with enhanced green 
fluorescence protein (EGFP) by PCR and 
inserted into expressing vector pET-22b. After 
expression and purification, EGFP-BP9 fusion 
protein was obtained. The purified products were 
analysed by SDS-PAGE and Western blot test 
(Fig 3A). The EGFP fusion proteins migrated at 
the expected sizes. 
 
To confirm whether EGFP-BP9 purified under the 
above-mentioned conditions could bind easily to 
tumour cells, a fluorescence microscope was 
used for direct observation. As shown in Fig 3B, 
the fluorescence was readily detected in the 
HepG2 and SMMC-7221cells treated with EGFP-
BP9, whereas the control EGFP failed under the 
same condition. Therefore, the EGFP-BP9 
possessed cellular binding ability to tumour cells. 
To investigate whether the EGFP-BP9 could bind 
to the cells over-expressing TfR and gain entry 
via the endocytic pathway, HepG2, SMMC-7221 
and L-O2 cells were examined by confocal 
microscopy. As shown in Fig 3C, the HepG2 and 
SMMC-7221 cells showed bright green 
fluorescence staining around the cell membrane. 
However, the L-O2 cells with lack of TfR only 
showed blue fluorescence background staining. 
These results suggested that EGFP-BP9 had 
selectivity and specificity abilities to HepG2 and 




Drug-resistant metastatic tumours and side 
effects are major limitations of conventional 
cancer therapy, such as irradiation and 
chemotherapy [16,17], necessitating the search 
for novel tumour-targeting agents. Transferrin 
receptors over-expressed in tumour cells, 
therefore, use the transferrin receptor as a target 
and the phage display technique to screen and 
obtain the transferrin receptor-specific binding 
short peptides, which may be expected to 
become the new tumour-targeting molecules. 
 
In the present work, we used a Ph.D.-7TM phage 
display library to screen TfR special binding 
peptides. In the process of the selection, 
screening conditions were gradually strict, the 
TfR concentration was gradually reduced, the 
Tween-20 concentration was gradually 
increased, and the elution time was extended. 
Through three rounds of selection, the phage  
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Figure 2: Competitive inhibition assay and inhibition of cells’ proliferation. (A) Competitive inhibition assay of the 
P9 phage clone binding to the cells by the synthetic peptide BP9 (□ = HepG2 cells/peptide BP9/P9 phage, △ = 
SMMC-7221 cells/peptide BP9/P9 phage, ◇ = HepG2 cells/peptide BP9/M13 phage, ○ = SMMC-7221 
cells/peptide BP9/M13 phage, ■ = L-O2 cells/peptide BP9/P9 phage). (B) Concentration dependent inhibition of 
peptide BP9 on the proliferation of cells (□ = HepG2 cells, △ = SMMC-7221 cells, ◇ = L-O2 cells). (C) Time 
dependent inhibition of peptide BP9 (0.001 mM) on the proliferation of cells (□ = HepG2 cells, △ = SMMC-7221 
cells, ◇ = L-O2 cells). The independent experiments were repeated four times. Data presented are the mean 
absorbance (±S.D.) of four samples. 
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Figure 3:  (A) SDS-PAGE and Western blot analyses of purified His-EGFP-BP9 fusion protein. Left panel, 
Coomassie Blue staining SDS-PAGE gel (Lane M, Molecular markers; lane 1, 2, purified His-EGFP-BP9; lane 3, 
4, purified control His-EGFP); right panel, Western blot using anti-EGFP antibody; (B) Binding of EGFP-BP9 
fusion protein on tumour cells. Cells were observed by fluorescence microscopy (Magnification ～ × 100). (C) 
Localisation of EGFP–BP9 fusion protein on tumour cells. Cells were observed by confocal laser microscopy 
(Magnification ～ × 40). 
 
clone P9 showed the highest affinity to TfR, 
examined by ELISA. A peptide competitive 
inhibition assay showed that when the synthetic 
peptide was pre-incubated with HepG2 and 
SMMC-7221 cells, the binding of phage P9 to 
cells was inhibited in a dose-dependent manner. 
Cell viability assay also had showed that BP9 
could inhibit the proliferation of the HepG2 and 
SMMC-7221 cells.  
 
In order to further research whether the P9 
phage display seven peptide can mediate other 
macromolecules to combine with TfR, P9 gen 
were fused with EGFP and connected to pET-
22b. After expression and purification, EGFP-
BP9 fusion protein was obtained. Through 
fluorescence microscopy, we found that EGFP-
BP9 could bind to HepG2 cells and SMMC-7221 
cells. However, the control groups could not. 
Further confocal laser microscopy was used to 
observe the localisation, we found fluorescence 
distributed mainly around the cell membrane, but 
we did not see the obvious cell plasma positive. 
These results show that the EGFP-BP9 fusion 
protein can combine with TfR on HepG2 cells 
and SMMC-7221 cells, and that BP9 has the 




This study describes an in vitro panning process 
used to select a peptide (designated BP9) 
capable of specifically binding to TfR. Peptide 
BP9 can inhibit the proliferation of the tumour 
cells over-expressing TfR and the DNA 
sequence coding for peptide BP9 is also able to 
target a macromolecule (EGFP) to combine with 
TfR. This suggests that the peptide BP9 may 
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